You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
--Plaque Psoriasis -- Adults - AJEMNYE is indicated for the treatment of adult patients (18 years or older) with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy.,--Plaque Psoriasis -- Paediatric population, 6 years and older - AJEMNYE is indicated for the treatment of moderate to severe plaque psoriasis in children and adolescent patients from 6 years of age who are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies.,--Psoriatic Arthritis (PsA) -- AJEMNYE, alone or in combination with methotrexate, is indicated for the treatment of signs and symptoms of active psoriatic arthritis in adult patients (18 years and older) where response to previous non-biological DMARD therapy has been inadequate.,--Crohns Disease -- AJEMNYE is indicated for the treatment of adult patients with moderately to severely active Crohns disease who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a TNFalpha antagonist or have medical contraindications to such therapies.,--Ulcerative Colitis -- AJEMNYE is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
This medicine is under additional monitoring as it is new or being used in a different way. You can help identify new safety information by reporting any side effects you may get.
--Plaque Psoriasis -- Adults - AJEMNYE is indicated for the treatment of adult patients (18 years or older) with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy.,--Plaque Psoriasis-- Paediatric population, 6 years and older - AJEMNYE is indicated for the treatment of moderate to severe plaque psoriasis in children and adolescent patients from 6 years of age who are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies.,--Psoriatic Arthritis (PsA) -- AJEMNYE, alone or in combination with methotrexate, is indicated for the treatment of signs and symptoms of active psoriatic arthritis in adult patients (18 years and older) where response to previous non-biological DMARD therapy has been inadequate.,--Crohns Disease -- AJEMNYE is indicated for the treatment of adult patients with moderately to severely active Crohns disease who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a TNF alpha antagonist or have medical contraindications to such therapies.,--Ulcerative Colitis -- AJEMNYE is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
This medicine is under additional monitoring as it is new or being used in a different way. You can help identify new safety information by reporting any side effects you may get.
--Plaque Psoriasis -- Adults - AJEMNYE is indicated for the treatment of adult patients (18 years or older) with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy.,--Plaque Psoriasis -- Paediatric population, 6 years and older - AJEMNYE is indicated for the treatment of moderate to severe plaque psoriasis in children and adolescent patients from 6 years of age who are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies.,--Psoriatic Arthritis (PsA) -- AJEMNYE, alone or in combination with methotrexate, is indicated for the treatment of signs and symptoms of active psoriatic arthritis in adult patients (18 years and older) where response to previous non-biological DMARD therapy has been inadequate.,--Crohns Disease -- AJEMNYE is indicated for the treatment of adult patients with moderately to severely active Crohns disease who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a TNF alpha antagonist or have medical contraindications to such therapies.,--Ulcerative Colitis-- AJEMNYE is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
This medicine is under additional monitoring as it is new or being used in a different way. You can help identify new safety information by reporting any side effects you may get.
--Crohns Disease-- AJEMNYE is indicated for the treatment of adult patients with moderately to severely active Crohns disease who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a TNF alpha antagonist or have medical contraindications to such therapies.,--Ulcerative Colitis-- AJEMNYE is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
This medicine is under additional monitoring as it is new or being used in a different way. You can help identify new safety information by reporting any side effects you may get.
Government Accredited with over 140 information partners
We are a government-funded service, providing quality, approved health information and advice
Healthdirect Australia acknowledges the Traditional Owners of Country throughout Australia and their continuing
connection to land, sea and community. We pay our respects to the Traditional Owners and to Elders both past and
present.
